aTYR PHARMA (ATYR) Non Operating Income (2018 - 2026)
aTYR PHARMA's (ATYR) quarterly Non Operating Income came in at $571000.0 in Q2 2026, down 26.89% on a YoY basis from $781000.0 in Q2 2025, and down 11.34% quarter-over-quarter from $644000.0 in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) Non Operating Income (2018 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported Non Operating Income for 9 consecutive years, with $571000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Income fell 26.89% year-over-year to $571000.0; the trailing twelve-month figure through Jun 2026 stood at $3.0 million (down 10.6% YoY), and the FY2025 full-year result was $3.5 million, down 9.97% from the prior year.
- Non Operating Income eased to $571000.0 in Q2 2026 per ATYR's latest filing, from $644000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.3 million in Q3 2023 and bottomed at $163000.0 in Q2 2022.
- Historically, Non Operating Income has averaged $788555.6 across 5 years, with a median of $843500.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income surged 646.01% in 2023, then tumbled 30.71% in 2024.
- Over 5 years, Non Operating Income stood at $427000.0 in 2022, then jumped by 180.56% to $1.2 million in 2023, then fell by 28.88% to $852000.0 in 2024, then retreated by 2.35% to $832000.0 in 2025, then plunged by 31.37% to $571000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $571000.0, $644000.0, and $832000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 571,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 571,000.00 |
| Mar 31, 2026 | 644,000.00 |
| Dec 31, 2025 | 832,000.00 |
| Sep 30, 2025 | 999,000.00 |
| Jun 30, 2025 | 781,000.00 |
| Mar 31, 2025 | 892,000.00 |
| Dec 31, 2024 | 852,000.00 |
| Sep 30, 2024 | 882,000.00 |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.15 Mn |
| Dec 31, 2023 | 1.20 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.22 Mn |
| Mar 31, 2023 | 835,000.00 |
| Dec 31, 2022 | 427,000.00 |
| Sep 30, 2022 | 247,000.00 |
| Jun 30, 2022 | 163,000.00 |
| Mar 31, 2022 | 224,000.00 |
| Dec 31, 2021 | 79,000.00 |
| Sep 30, 2021 | 59,000.00 |